| 词条 | Elotuzumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457123959 | image = | type = mab | mab_type = mab | source = zu | target = SLAMF7 (CD319) | tradename = Empliciti | pregnancy_AU = | pregnancy_US = X | pregnancy_category = X (used with lenalidomide) | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = ℞-only | legal_status = | routes_of_administration = IV | bioavailability = 100% (IV) | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 915296-00-3 | ATC_prefix = L01 | ATC_suffix = XC23 | PubChem = | IUPHAR_ligand = 8361 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB06317 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 1351PE5UGS | KEGG = D09337 | C=6476 | H=9982 | N=1714 | O=2016 | S=42 | molecular_weight = 145.5 kg/mol }}Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma.[1] The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody.[2] Approvals and indicationsMultiple myelomaIn May 2014, it was granted "Breakthrough Therapy" designation by the FDA (for multiple myeloma).[3] On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications.[1] Elotuzumab was labeled for use with lenalidomide and dexamethasone. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen.[2] In May 2016 the EC/EU gave a similar approval.[4] References1. ^1 {{cite web|title=Press Announcement—FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm|website=U.S. Food and Drug Administration|accessdate=3 December 2015}} 2. ^1 {{cite web|title=Empliciti (elotuzumab) for Injection, for Intravenous Use. Full Prescribing Information |url=http://packageinserts.bms.com/pi/pi_empliciti.pdf |website=Empliciti (elotuzumab) for US Healthcare Professionals |publisher=Bristol-Myers Squibb Company|location=Princeton, New Jersey|deadurl=yes |archiveurl=https://web.archive.org/web/20151208064304/http://packageinserts.bms.com/pi/pi_empliciti.pdf |archivedate=2015-12-08 |df= }} 3. ^{{cite press release |url=http://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-abbvie-receive-us-fda-breakthrough-therapy-designatio |title=Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma |location=Princeton, New Jersey and North Chicago, Illinois |date=2014-05-19 |accessdate=2015-02-05 |publisher=Bristol-Myers Squibb}} 4. ^BMS gets two new cancer approvals in Europe. May 2016 External links
2 : Monoclonal antibodies for tumors|Breakthrough therapy |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。